Prioritise protein sufficiency first, then assess micronutrients
Research Dose Ranges Preclinical animal studies: 110 mcg/kg (nanogram to microgram range) once or twice daily Extrapolated human equivalent range commonly discussed in clinical literature: 200500 mcg/day Human pilot IV data: doses up to 20 mg were tolerated without adverse effects in two healthy adults (Lee & Burgess, 2025) though this is far above typical outpatient dosing Protocol: Musculoskeletal / Connective Tissue Healing For tendon, ligament, or muscle injury recovery, the standard approach in clinical functional medicine practice involves: SubQ injection at 200500 mcg once daily , injected near (not into) the injury site Cycle length: typically 48 weeks , with reassessment Often combined with TB-500 (thymosin beta-4) for synergistic tissue remodeling the BPC+TB stack Best results seen alongside physical therapy, not as a substitute for it Protocol: Gut and GI Mucosal Healing For IBD, gut permeability, NSAID damage, or H
Suitability Assessing your current and past medical history to make sure its safe for you
Pacing means doing less than you think you can on good days, so you avoid pushing yourself into a longer recovery
RYBELSUS : A1C reduction demonstrated at 52 weeks Statistically significant A1C reduction vs Jardiance 2* Statistically significant A1C control vs Jardiance 2* PIONEER 2 study design 1,2 In an open-label trial with a primary endpoint of mean change in A1C from baseline to 26 weeks, 822 adult patients with type 2 diabetes on metformin were randomized to RYBELSUS 14 mg (n=411) or Jardiance 25 mg (n=410), both once daily
